MENU
+Compare
ANIX
Stock ticker: NASDAQ
AS OF
Jan 23, 04:37 PM (EDT)
Price
$2.90
Change
-$0.07 (-2.36%)
Capitalization
90.47M

ANIX Anixa Biosciences Forecast, Technical & Fundamental Analysis

a developer of non-invasive blood tests for the early detection of solid tumor based cancers

Industry Biotechnology
ANIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ANIX with price predictions
Jan 08, 2025

ANIX in upward trend: price may jump up because it broke its lower Bollinger Band on December 31, 2024

ANIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 41 cases where ANIX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where ANIX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ANIX advanced for three days, in of 235 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ANIX entered a downward trend on January 08, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ANIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.789) is normal, around the industry mean (15.076). P/E Ratio (0.000) is within average values for comparable stocks, (88.202). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.833). ANIX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (384.615) is also within normal values, averaging (264.879).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
ANIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ANIX is expected to report earnings to fall 21.36% to -8 cents per share on March 14

Anixa Biosciences ANIX Stock Earnings Reports
Q1'25
Est.
$-0.09
Q4'24
Missed
by $0.02
Q3'24
Est.
$-0.10
Q2'24
Beat
by $0.01
Q1'24
Missed
by $0.01
The last earnings report on January 01 showed earnings per share of -10 cents, missing the estimate of -8 cents. With 57.34K shares outstanding, the current market capitalization sits at 90.47M.
A.I. Advisor
published General Information

General Information

a developer of non-invasive blood tests for the early detection of solid tumor based cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Computer Peripherals
Address
3150 Almaden Expressway
Phone
+1 408 708-9808
Employees
5
Web
https://www.anixa.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TWST52.341.89
+3.75%
Twist Bioscience Corp
CURV6.410.14
+2.23%
Torrid Holdings
ACRS2.60N/A
N/A
Aclaris Therapeutics
CODYY18.35N/A
-0.03%
Compagnie de Saint-Gobain
G45.81-0.35
-0.76%
Genpact Limited

ANIX and Stocks

Correlation & Price change

A.I.dvisor tells us that ANIX and GERN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ANIX and GERN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANIX
1D Price
Change %
ANIX100%
+5.87%
GERN - ANIX
32%
Poorly correlated
+1.01%
RYTM - ANIX
28%
Poorly correlated
-0.50%
PRTA - ANIX
27%
Poorly correlated
+2.27%
CDTX - ANIX
27%
Poorly correlated
-0.86%
DNLI - ANIX
27%
Poorly correlated
+1.17%
More